FDA Inspection 1315626 — Novartis Pharma S.A.S. - Centre de Biotechnologie
The FDA completed an inspection of Novartis Pharma S.A.S. - Centre de Biotechnologie on May 23, 2025 in Huningue. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- May 23, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Huningue (France)
Additional Details
Mutual Recognition Agreement (MRA)